10-2002: Recombinant anti- human ErbB2/HER2 Antibody (Trastuzumab)

**Clonality**: Monoclonal  
**Clone Name**: ABM2A1G1  
**Application**: Functional Assay, FACS  
**Reactivity**: Human  
**Gene**: ERBB2  
**Gene ID**: 2064  
**Uniprot ID**: P04626  
**Format**: Purified  
**Alternative Name**: ERBB2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, CD340; HER 2; HER2; NEU; herstatin; p185erbB2; proto-oncogene Neu; c-erb B2/neu protein; proto-oncogene c-ErbB-2.

**Description**

**Target**: ErbB2  
**Trade name**: Samceptin  
**Generic name**: Trastuzumab  
**Product Origin**: Recombinant in CHO cells  
**Product Construction**: Immunoglobulin G1, anti-(human p185neu receptor) (human-mouse monoclonal rhuMab HER2 g1-chain), disulfide with human-mouse monoclonal rhuMab HER2 light chain, dimer.

The drug Trastuzumab (Brand name Herceptin®, From Roche/Genentech) is a monoclonal antibody and works by targeting breast cancer cells that overexpress the HER2 protein. Overexpression (or amplification) of the HER2 protein is associated with accelerated cell division. By binding to the protein receptors on these cells, Trastuzumab interrupts the growth signal, thereby slowing the growth and spread of tumors. Approximately 20% of breast cancers overexpress the HER2 protein. Amplification of HER2 in breast cancer cells has been correlated with adverse prognostic factors such as large tumor size, high nuclear grade, and decreased expression of estrogen and progesterone hormone receptors. HER2 amplification has also been associated with reduced disease-free survival, and overall survival, for women with node-positive or node negative disease. Trastuzumab (anti-p185, rhuMab HER2), which is a humanized monoclonal antibody that binds to the HER2 protein. HER-2 is a transmembrane spanning receptor-like protein, which is structurally related to the epidermal growth factor receptor and has been shown to inhibit the proliferation of human tumor cells that overexpress HER2 both *in vitro* and *in vivo*. The developed biosimilar to Herceptin, designated as Samceptin. The biochemical characterizations and the functional assays suggest that Samceptin is highly similar in structure and activity to Herceptin.

*Disclaimer: Herceptin® is a registered trademark of Genentech, Inc. Samceptin can only be used for research purposes. Not to be used as diagnostic for therapeutic purposes.*

**Product Info**

**Amount**: 100 µg  
**Purification**: Purity: >98.0% as determined by SEC-HPLC & SDS-PAGE.  
**Content**: 10mM Phosphate pH-7.0, 150 mM NaCl, 20% Glycerol  
**Storage condition**: Store the antibody at 4°C, stable for 6 months. For long-term storage, store at -20°C. Avoid repeated freeze and thaw cycles.

**Amino Acid**: PepMap Analysis of N terminal amino acids sequence: H chain: EVQLVESGGGLVQPG, L chain: DIQMTQSPSSLSASV

*For Research Use Only. Not for use in diagnostic/therapeutics procedures.*
**Application Note**

The biological activities of Samceptin was compared with commercially available innovator drug, Herceptin from Roche.

**Recommended dilutions:** FACS: 1-2 µg/10^6 cells, ADCC: 20-25 mg/ml. However, this need to be optimized based on the research applications.

---

**Figure-1:** Antiproliferative activity of Samceptin was assayed in comparison with Herceptin using ADCC Reporter Bioassay Kit from Promega (Cat #G7010) in SK-BR-3 cells. Result indicated that Samceptin potency is at par with Herceptin.

**Figure-2:** Antiproliferative activity of Samceptin was assayed in comparison with Herceptin using ADCC Reporter Bioassay Kit from Promega (Cat #G7010) in MCF-7 cells. Result indicated that Samceptin potency is at par with Herceptin.

**Figure-3:** SEC-HPLC analysis of Herceptin and Samceptin. Based on this analysis, Samceptin is highly pure and purity estimated to be >98%.

**Figure-4:** Reducing SDS-PGE of Samceptin (Lane-1) in comparison with Herceptin (Lane-2). Lanes were overloaded to show the presence of any other protein bands than Samceptin. Both heavy and light chains are well separated.
Figure-5: Epitope binding study by flow cytometric analysis. BT-474 cells expressing HER2 antigen were treated with Herceptin and Samceptin (2 µg/10^6 Cells). Surface staining was done using FITC conjugated antibodies.

Figure-6: Epitope binding study by flow cytometric analysis. MCF-7 cells expressing HER2 antigen were treated with Herceptin and Samceptin (2 µg/10^6 Cells). Surface staining was done using FITC conjugated antibodies.